Skip to main content

Table 1 Threshold dose prices for various vaccination strategies, considering a two-dose schedule

From: Assessing the cost-effectiveness of HPV vaccination strategies for adolescent girls and boys in the UK

Vaccination strategy £, versus halted vac. (3.5%) £, versus girls’ vac. (3.5%) £, versus halted vac. (1.5%) £, versus girls’ vac. (1.5%)
Girls, bivalent 55.80 (55.04 – 56.57) - 687.47 (675.62 – 699.20) -
Girls, quadrivalent 99.64 (98.90 – 100.37) - 752.46 (740.51 – 764.72) -
Girls, nonavalent 108.05 (107.36 – 108.75) - 811.44 (801.18 – 821.68) -
Girls & boys, bivalent 25.08 (24.64 – 25.52) -5.67 (-6.42 – -4.93) 361.99 (356.09 – 367.85) 36.46 (26.82 – 45.98)
Girls & boys, quadrivalent 48.38 (47.95 – 48.80) -2.92 (-3.64 – -2.18) 398.68 (392.65 – 404.84) 44.70 (35.42 – 53.81)
Girls & boys, nonavalent 52.77 (52.42 – 53.10) -2.56 (-3.13 – -1.99) 429.26 (422.98 – 435.44) 46.88 (37.63 – 56.46)
  1. Mean values shown over 500 simulations, with 95% confidence intervals in brackets. All strategies assume a £20,000 cost-effectiveness threshold for a QALY, with both 3.5% and 1.5% discount rates applied, and a £10 administration charge per dose. When comparing a strategy to girls-only vaccination the same vaccine is used for correct comparison